

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA

ABN 84 152 713 098

FINANCIAL REPORT

for the year ended 30 June 2016

CONTENTS

| | Page |
|--|------|
| 1. Directors' Report | 3 |
| 2. Auditor's Independence Declaration | 8 |
| 3. Financial Report | |
| Statement of Profit or Loss Other and Comprehensive Income | 9 |
| Statement of Changes in Equity | 10 |
| Statement of Financial Position | 11 |
| Statement of Cash Flows | 12 |
| Notes to the Financial Statements | 13 |
| 4. Directors' Declaration | 17 |
| 5. Independent Auditor's Report to the Members | 18 |

This Financial Report covers National Stem Cell Foundation of Australia ('the Company') as an individual entity. National Stem Cell Foundation of Australia is a Company limited by guarantee, incorporated and domiciled in Australia.

The Company's registered office and principal place of business is:

Suite 5
242 Hawthorn Road
Caulfield Victoria 3162

A description of the nature of the Company's operations and its principal activities is included in the Directors' Report on pages 3 to 7 which is not part of this Financial Report.

The Financial Report was authorised for issue by the directors on 15 August 2016. The directors have the power to amend and reissue the Financial Report.

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

The directors present their report together with the Financial Report of National Stem Cell Foundation of Australia for the year ended 30 June 2016 and the Auditor's Report thereon.

Directors

The directors of the Company at any time during or since the end of the year are:

| <i>Name</i> | <i>Age</i> | <i>Period of directorship, special responsibilities, experience, other current directorships and former directorships in the last three years</i> |
|---|------------|--|
| Dr Graeme Blackman OAM, PhD, BSc (Hons), BD, MTheol, FTSE, FRACI, FAICD, FloD (Non-Executive Director, Chairman) | 70 | Independent non-executive director and Chairman of the Company, appointed 17 August 2011. Dr Blackman is a former Professor of Pharmaceutical Chemistry at the Victorian College of Pharmacy. He is a non-executive director of IDT Australia Ltd, an Australian Securities Exchange (ASX) listed public company operating in the pharmaceutical industry. He was a director of the Australian Stem Cell Centre. He has been or continues to be a member of various Commonwealth and State advisory committees and working groups in pharmaceuticals and biotechnology, including the Australian Biotechnology Advisory Council, the Pharmaceutical Industry Working Group and the Pharmaceutical Industry Strategy Group. He chaired the Australian Government's Pharmaceuticals Industry Action Agenda, which developed a policy framework for the industry over a ten year period. |
| Emeritus Professor Graham Macdonald AM, MD, BS, BSc (Med), FRACP, FRCP, FANZCC (Non-Executive Director, Deputy Chairman) | 79 | Independent non-executive director and Deputy Chairman of the Company appointed 29 September 2011. Professor Macdonald brings a wealth of experience in clinical medicine, basic biomedical science and in the field of licensing and commercialisation to the Company. He has had an outstanding career first as an academic nephrologist, and then moving into the pharmaceutical industry with Merck Sharp and Dohme (Australia). Graham is currently a director and Chairman of Vectus Biosciences Limited and director and chairman of Stem Cells Limited. In June 2012 Professor Macdonald received an Australian Queen's Birthday Honour in the General Division of the Order of Australia for "service to biomedical research in the areas of hypertension and renal disease, to medical education, to the promotion and awareness raising of organ donation, and as a mentor". |
| Emeritus Professor Richard Smallwood AO, MB, BS, MD, FRACP, FRCP, FACP (Hon) (Non-Executive Director) | 79 | Independent non-executive director appointed 17 August 2011. Professor Smallwood is Emeritus Professor of Medicine, University of Melbourne. As Professor of Medicine within the University of Melbourne, he was Head of the Department of Medicine, Chairman of the Division of Medicine and Director of Gastroenterology at the Austin and Repatriation Medical Centres. Professor Smallwood was President of the Royal Australasian College of Physicians from 1996 to 1998 and was Chief Medical Officer of Australia from 1999 to 2003. Professor Smallwood has served as a chair of a large number of organisations including the National Health and Medical Research Council (NHMRC), the National Influenza Pandemic Advisory Council, the National Health Information Management Advisory Council, the National Health Priority Action Council, the National Blood Authority and the Ministerial Taskforce for Cancer in Victoria. Professor Smallwood was President of the Australian Medical Council from 2008 to 2013. He was until 2010 a member of the Board of Governance of the Victorian Health Promotion Foundation and, until 2009, a director of the Murdoch Children's Research Institute. He was a director of the Australian Stem Cell Centre. |
| Mr Stuart Gooley BComm (Melb), FCA, FCPA (Non-Executive Director) | 71 | Independent non-executive director and Chairman of the Finance, Audit and Risk Management Sub-committees appointed 17 August 2011. Mr Gooley had a 42 year period in the accounting profession with Arthur Andersen and Ernst & Young, and retired from public practice in 2008. During his career he was the Australian head of Andersen's Accounting and Audit practice and the Asia Pacific Risk Management Practice Director. Mr Gooley was the Victorian State President of CPA Australia in 1994, and served on the Australian Auditing and Assurance Standards Board and the International Auditing Practices Committee. Outside of the accounting profession he has served on the board of two educational institutions, and is currently a director of Lahaina Holdings Pty Ltd, Tai Tam Investments Pty Ltd and Wilson Transformer Company. He is also a member of the resources committee of the Royal Australian College of Surgeons. He was a director of the Australian Stem Cell Centre. |

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

| <i>Name</i> | <i>Age</i> | <i>Period of directorship, special responsibilities, experience, other current directorships and former directorships in the last three years</i> |
|--|------------|---|
| Dr Peter Riddles BSc (Hons), PhD, Grad Dip Bus (Management), FAICD (Non-Executive Director) | 62 | Independent non-executive director appointed 29 September 2011. Dr Riddles has extensive experience in biotechnology having served as director on many start-up enterprises, and having worked with universities and with the private sector. He is presently Chairman of the Griffith University Enterprise Board and is a Board Member of the Hear and Say Centre, and the CSIRO. He is presently a member of the Entrepreneurs Program Committee of Innovation and Science Australia, and the Director of ViciBio Pty Ltd, a company that provides services to organisations involved in science, technology commercialisation and innovation. Earlier he has served on diverse boards in the private and public sector concerning innovation and biotechnology including Innovation Australia, the Industry Research and Development Board, and the Australian Stem Cell Centre. |
| Mr David Collins MEng, MBA, CA, GAICD (Non-Executive Director) | 51 | Independent non-executive director and member of the Finance, Audit and Risk Management Sub-committees appointed 16 December 2011. Mr Collins is a partner in an accountancy and consultancy firm and has previously held senior executive positions in companies in Europe and the UK within the media industry. Mr Collins was Chief Executive Officer of the Australian Stem Cell Centre from September 2009 until November 2011. |
| Dr Karin Tiedemann OAM, MBBS, FRACP (Non-Executive Director) | 68 | Independent non-executive director appointed 15 December 2014. Dr Tiedemann practiced for more than 30 years as a paediatric haematologist and oncologist in the Children's Cancer Centre at The Royal Children's Hospital (RCH) in Melbourne prior to retirement from clinical practice in 2014. Dr Tiedemann established the haemopoietic stem cell transplant program at RCH in 1981, heading the program until 2011. She was pivotal in obtaining the support of the Bone Marrow Donor Institute in establishing an umbilical cord blood stem cell bank at the RCH thus expanding donor availability to many children previously unable to locate a donor and therefore unable to proceed to transplantation for recurrent leukaemia or other lethal marrow disorders. She was a founding member of the Australian and New Zealand Children's Haematology and Oncology Group, served on the executive and on subcommittees, contributing to advances in treatment that have resulted not only in high cure rates but also a lowering of the long term side effects of cancer treatment for infants, children and adolescents. Dr Tiedemann is the Medical Director of the BMDI Cord blood Bank, a member of the BMDI CBB Management Committee and of Auscord, the national network of cord blood banks. She served on the Clinical Ethics Response Group at RCH and on the Ethics Committee of the Australian Bone Marrow Donor Registry. |
| Associate Professor Caroline Gargett MD, PhD (Non-Executive Director) | 64 | Independent non-executive director appointed 15 December 2014. Associate Professor Gargett is currently Deputy Director (Women's Health) at the Ritchie Centre, Hudson Institute of Medical Research and is also a National Health & Medical Research Council (NHMRC) Senior Research Fellow. In 2002 Associate Professor Gargett discovered adult stem cells in the endometrium, the lining of the uterus, changing our understanding of how the endometrium regenerates each month. She leads a collaborative project with the CSIRO Future Manufacturing Flagship to investigate the use of endometrial mesenchymal stem cells for a tissue engineering application in pelvic floor prolapse surgery. Her research findings are promising for the development of potential therapeutics. Associate Professor Gargett has served as President of the Australasian Society for Stem Cell Research (2013-2014) and is on the Boards for Biology of Reproduction, Reproductive Sciences and is an Associate Editor of Reproductive Sciences. |

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Company Secretary and Executive Officers

| <i>Name</i> | <i>Age</i> | <i>Period of office, special responsibilities and experience</i> |
|--|------------|--|
| Mr Graeme Mehegan BBus(Acc), FCPA, FCIS (Company Secretary) | 61 | <p>Mr Mehegan was appointed Company Secretary 8 November 2011. Mr Mehegan was Chief Financial Officer for the Australian Stem Cell Centre from August 2009 until November 2011. He was Chief Financial Officer and Company Secretary for Pioneer Electronics Australia from January 2001 until March 2008 and prior to that held senior financial roles including the position of Company Secretary with Random House Australia and Pitman Publishing, both in the book publishing industry.</p> |
| Ms Julia Mason MBA (Chicago), FFin, MAICD (Executive Officer) | 47 | <p>Executive Officer appointed on 19 February 2015. Ms Mason has a 20 year plus career focused on creating growth and value, in the private and not for profit sectors in both Australia and Asia, across the advertising, finance and oil industries. She has held senior commerce and finance positions at Sensis and BP. Ms Mason is a director of the Transport Accident Commission (TAC) Board of Victoria and was previously Chairman of the Victorian State Emergency Services (VICSES), One in Five, and a director with VicUrban. Ms Mason has also lectured in corporate finance in the masters program with FinSia, the former Securities Institute of Australia. Ms Mason was previously a director with Same Business Different Outcome (SBDO), a Melbourne-based private equity business sourcing operational expertise and capital to back growth businesses.</p> |

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Principal activities

The National Stem Cell Foundation of Australia is an Australian Tax Office (ATO) registered Health Promotion Charity dedicated to promoting the study and responsible use of stem cells to reduce the burden of disease.

The Foundation's priorities are:

- Supporting research that pursues cures for as-yet-untreatable diseases
- Building a community of people with a shared interest in stem cell science
- Providing the Australian public with objective, reliable information on both the potential and risks of stem cell medicine.

Short-term objectives

The Company funds a broad program of activities that will support Stem Cell Science in Australia. It is also taking steps to dramatically increase fundraising income from various sources.

Long-term Objectives

The Company's long-term objectives are to:

- Pursue the cures for, as yet, untreatable diseases and illnesses, using stem cell technology and regenerative medicine techniques by supporting research activities in these areas.
- Provide resources to develop objective information and to educate and inform the Australian public on stem cell technology and regenerative medicine including its risks, achievements, benefits and overall technical progress.

Strategy for achieving short and long-term objectives

To achieve these objectives, the Company will draw heavily on the experience of its Board of Directors, Executive Officer and Company Secretary who (as a group) have considerable and varied experience in medical research, business management and finance.

The Board will seek to appoint experts in various fields where specialised expertise and scientific advice is required including:

- Investment strategy
- Website development and marketing
- Promotion and public relations

Given the nature of its activities and the Health Promotion Charity status of the Company, the Board has successfully obtained some services on a pro-bono basis but in other cases has found it necessary to enlist external paid consultants.

This year the Foundation provided philanthropic financial support for the following health promotion activities in support of Australian stem cell science:-

- **Awarded the third round of NSCFA Metcalf Prizes (worth \$50,000 each)** to James Chong and Tracy Heng
- **Provided support** for over 50 PhD students and Early Career Researchers to attend and present at the Australasian Society of Stem Cell Researchers (ASSCR) Conference in the Hunter Valley, New South Wales
- **Sponsored** the 7th International EMT (Epithelial-Mesenchymal Transition) conference in Melbourne and the New South Wales Stem Cell Network conference in Sydney
- **Provided** funding for the ASSCR Integrated Public Education Project

Additionally during the year the Foundation published 4 newsletters, and responded to more than 30 inquiries from members of the public.

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Directors' meetings

The number of directors' meetings (including meetings of committees of directors) and number of meetings attended by each of the directors of the Company during the year were:

| | Directors' Meetings | | Finance, Audit and Risk Management Sub-Committee Meetings | | Science and Ethics Sub-Committee Meetings | |
|---------------------------|---------------------|----------|---|----------|---|----------|
| | Attended (ii) | Held (i) | Attended (ii) | Held (i) | Attended (ii) | Held (i) |
| Dr G Blackman | 4 | 4 | 4 | 5 | - | - |
| Emeritus Prof G Macdonald | 3 | 4 | - | - | 3 | 4 |
| Emeritus Prof R Smallwood | 4 | 4 | - | - | 4 | 4 |
| Dr P Riddles | 3 | 4 | - | - | - | - |
| Mr S Gooley | 4 | 4 | 5 | 5 | - | - |
| Mr D Collins | 4 | 4 | 4 | 5 | - | - |
| Dr K Tiedemann | 4 | 4 | - | - | 4 | 4 |
| Assoc Prof C Gargett | 4 | 4 | - | - | 4 | 4 |

- (i) Represents the number of meetings held during the time that the director held office or was a member of the committee during the year.
- (ii) Director either attended or their duly appointed alternate director attended on their behalf.

The Finance, Audit and Risk Management Sub-committee is chaired by Mr S Gooley and its role is to review the implementation of the risk management processes, financial reporting, internal control and management of financial risks, the audit process, and the Company's process for monitoring compliance with laws and regulations.

The Foundation's Science and Ethics Committee is chaired by Emeritus Prof G Macdonald. It is responsible for providing the Board with information and guidance on the current state of stem cell science, research activities in the area, ethical issues that arise and how they have been dealt with by regulatory bodies or governments. The Committee also oversees the Foundation's major research support activity, the selection of recipients of two Metcalf prizes annually for mid-career researchers in stem cell science, and is responsible for replying to over thirty enquiries a year from members of the public seeking information about stem cell treatments.

Contribution in Winding Up

The Company is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the Company is wound up the constitution states that each member is required to contribute a maximum of \$100 each towards meeting any outstanding obligations of the entity. At 30 June 2016, the total amount that members of the Company are liable to contribute if the Company is wound up is \$800.

Auditors' independence declaration

A copy of the auditors' independence declaration as required under section 60-40 of the *Australian Charities and Not-for-profits Commission Act 2012* is set out on page 8.

Dated at Melbourne this 15th day of August 2016.

Signed in accordance with a resolution of the directors.



Dr Graomo Blackman
(Chairman)

The Rialto, Level 30
525 Collins St
Melbourne Victoria 3000

Correspondence to:
GPO Box 4736
Melbourne Victoria 3001

T +61 3 8320 2222
F +61 3 8320 2200
E info.vic@au.gt.com
W www.grantthornton.com.au

Auditor's Independence Declaration
To the Directors of National Stem Cell Foundation of Australia

In accordance with the requirements of section 60-40 of the Australian Charities and Not-for-profits Commission Act 2012, as lead auditor for the audit of National Stem Cell Foundation of Australia for the year ended 30 June 2016, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the Australian Charities and Not-for-profits Commission Act 2012 in relation to the audit; and
- b no contraventions of any applicable code of professional conduct in relation to the audit.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants

Eric W Passaris

Eric Passaris
Partner - Audit & Assurance

Melbourne, 15 August 2016

Grant Thornton Audit Pty Ltd ACN 130 913 594
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation. Liability is limited in those States where a current scheme applies.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME for the year ended 30 June 2016

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA ABN 84 152 713 098

| Statement of profit or loss and other comprehensive income for the year ended 30 June 2016 | Note | Year Ended 30 June 2016 | Year Ended 30 June 2015 |
|---|------|----------------------------|----------------------------|
| | | \$ | \$ |
| Revenues | 2 | 287,669 | 363,957 |
| Administrative costs | 3 | (130,087) | (152,668) |
| Promoting stem cell science and projects | 3 | (174,751) | (250,993) |
| Gain on disposal of investments | | 9,537 | - |
| Loss before income tax | | (7,632) | (39,704) |
| Income tax expense | | - | - |
| Loss for the year | | (7,632) | (39,704) |
| Other comprehensive income | | | |
| <i>Items that may be reclassified subsequently to profit or loss</i> | | - | |
| Changes in the fair value of available for sale financial assets | | (236,969) | (28,720) |
| Other comprehensive income for the year | | (236,969) | (28,720) |
| Total comprehensive income for the year | | (244,601) | (68,424) |

This Statement of profit or loss and other comprehensive income is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 16.

STATEMENT OF CHANGES IN EQUITY

for the year ended 30 June 2016

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA ABN 84 152 713 098

| Statement of changes in equity | | | |
|--|---|------------------------------|---------------------|
| For the year ended 30 June 2016 | AFS Financial Instrument Reserve | Retained Earnings | Total Equity |
| | \$ | \$ | \$ |
| Total equity at the beginning of the financial year | 298,319 | 4,061,093 | 4,359,412 |
| Loss for the year | | (7,632) | (7,632) |
| Changes in fair value of available for sale financial assets | (236,969) | - | (236,969) |
| Total comprehensive income for the year | (236,969) | (7,632) | (244,601) |
| Total equity at the end of the financial year | 61,350 | 4,053,461 | 4,114,811 |

| For the year ended 30 June 2015 | AFS Financial Instrument Reserve | Retained Earnings | Total Equity |
|--|---|------------------------------|---------------------|
| | \$ | \$ | \$ |
| Total equity at the beginning of the financial year | 327,039 | 4,100,797 | 4,427,836 |
| Loss for the year | | (39,704) | (39,704) |
| Changes in fair value of available for sale financial assets | (28,720) | | (28,720) |
| Total comprehensive income for the year | (28,720) | (39,704) | (68,424) |
| Total equity at the end of the financial year | 298,319 | 4,061,093 | 4,359,412 |

This Statement of changes in equity is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 16.

Statement of financial position

as at 30 June 2016

| | Note | 2016 | 2015 |
|-----------------------------------|------|------------------|------------------|
| | | \$ | \$ |
| Current assets | | | |
| Cash and cash equivalents | 4 | 659,873 | 203,264 |
| Trade receivables and prepayments | 5 | 112,787 | 145,997 |
| Investments | 6 | 3,398,350 | 4,023,319 |
| Total current assets | | 4,171,010 | 4,372,580 |
| Non current assets | | | |
| Plant & Equipment | | 138 | 521 |
| Total non current assets | | 138 | 521 |
| Total assets | | 4,171,148 | 4,373,101 |
| Current liabilities | | | |
| Trade and other payables | 7 | 55,125 | 13,181 |
| Short-term employee benefits | | 1,212 | 508 |
| Total current liabilities | | 56,337 | 13,689 |
| Total liabilities | | 56,337 | 13,689 |
| Net assets | | 4,114,811 | 4,359,412 |
| Equity | | | |
| Retained earnings | 8 | 4,053,461 | 4,061,093 |
| Other reserves | 8 | 61,350 | 298,319 |
| Total equity | | 4,114,811 | 4,359,412 |

This Statement of financial position is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 16.

STATEMENT OF CASH FLOWS

for the year ended 30 June 2016

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Statement of cash flows

for the period ended 30 June 2016

Note

**Year Ended
30 June 2016****Year Ended
30 June 2015**

| | | \$ | \$ |
|--|---|------------------|-----------|
| Cash flows from operating activities | | | |
| Profit / (Loss) after related income tax | | (7,632) | (39,704) |
| Adjustments for: | | | |
| Depreciation & Amortisation | | 383 | 861 |
| Change in assets and liabilities: | | | |
| Trade and other receivables | | 33,210 | (22,844) |
| Short term employee benefits | | 704 | - |
| Trade and other payables | | 41,944 | (59,075) |
| Net cash Inflow / (outflow) from operating activities | | 68,609 | (120,762) |
| Cash flows from investing activities | | | |
| Interest | | - | - |
| Proceeds from sales of investments | | 1,188,000 | 550,000 |
| Payments for new investments | | (800,000) | (600,000) |
| Net cash inflow / (outflow) from investing activities | | 388,000 | (50,000) |
| Cash flows from financing activities | | - | 500 |
| Net cash inflow from financing activities | | - | 500 |
| Net Increase/(Decrease) in cash held | | 456,609 | (170,262) |
| Cash and cash equivalents at the beginning of the period | | 203,264 | 373,526 |
| Cash and cash equivalents at the end of the period | 4 | 659,873 | 203,264 |

This Statement of cash flows is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 16.

1 Summary of significant accounting policies

The principal accounting policies set out below have been consistently applied, unless otherwise stated.

a) Basis of preparation

This general purpose Financial Report has been prepared in accordance with Australian Accounting Standards – Reduced Disclosure Requirements, other authoritative pronouncements of the Australian Accounting Standards Board and the *Australian Charities and Not-for-profits Commission Act 2012*.

These financial statements have been prepared under the historical cost convention, modified by the revaluation of available-for-sale financial assets.

b) Foreign currency*Functional and presentation currency*

Items included in the financial statements of the Company are measured and presented in Australian dollars.

Transactions and balances

Foreign currency transactions are initially translated into Australian currency using the exchange rates prevailing at the date of each transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.

c) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will follow and the revenue can be reliably measured. All revenue is stated net of the amount of goods and services tax (GST).

Donations revenue:

Donations are only brought to account when the funds are received into the bank account, that is, when control over the funds is established, or the right to receive the funds has been recognised.

Investment revenue:

Receipts associated with dividends are recognised as revenue when the right to receive payment has been established.

Interest revenue:

Interest revenue is recognised when the right to receive the revenue has been established.

Other revenue:

Other revenue is recognised when the right to receive the revenue has been established.

Franking credits:

Franking credits are recognised when the right to receive the revenue has been established and can be reliably measured.

d) Income tax

The Company has received a private ruling from the Australian Taxation Office (ATO) to receive exemption from income tax pursuant to the provisions of section 50-5 of the *Income Tax Assessment Act 1997*. The Company currently considers that it will continue to be exempt under the self assessment system applying under section 50-5 of the *Income Tax Assessment Act 1997*.

e) Trade and other payables

These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial period and which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition.

f) Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the amount of GST incurred is not recoverable from the ATO. In this case it is recognised as part of the cost of acquisition of the asset or as part of an item of expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included as a current asset or liability in the balance sheet.

The GST components of cash flows arising from investing and financing activities which are recoverable from, or payable to, the ATO are classified as operating cash flow.

g) Cash and cash equivalents

For cash flow statement presentation purposes, cash and cash equivalents includes deposits at call with financial institutions and other highly liquid investments with short periods to maturity that are readily convertible to cash on hand and are subject to an insignificant risk of changes in value.

h) Investments

Investments are categorised as available-for-sale assets. After initial recognition, available-for-sale assets are measured at fair value with gains or losses being recognised as a separate component of equity until the investment is derecognised or until the investment is determined to be impaired, at which time the cumulative gain or loss previously reported in equity is recognised in profit or loss.

i) Critical accounting estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances. In the preparation of the financial statements for the period ended 30 June 2016, there have been no areas involving a high degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements.

| | Note | Year Ended 30 June 2016 | Year Ended 30 June 2015 |
|--|------|----------------------------|----------------------------|
| | | \$ | \$ |
| 2 Revenue | | | |
| Donations and bequeathments | | 26,676 | 21,496 |
| Income from investments | | 250,047 | 320,113 |
| Interest income | | 10,926 | 7,916 |
| Other | | 20 | 14,432 |
| Total revenue | | 287,669 | 363,957 |
| 3 Expenses | | | |
| Expenditure classified by function | | | |
| Administrative Expenses | | | |
| - Salaries and on-costs | | 69,794 | 71,385 |
| - Directors expenses | | 3,471 | 9,278 |
| - Professional fees | | 31,113 | 37,740 |
| - Insurance | | 3,627 | 2,887 |
| - Other administration expenses | | 22,082 | 31,378 |
| Expenses incurred in promoting Stem Cell Science including projects | | 174,751 | 250,993 |
| Total expenditure | | 304,838 | 403,661 |
| 4 Cash and cash equivalents | | | |
| Cash at bank and on hand | | 208,861 | 83,264 |
| Term Deposits | | 451,012 | 120,000 |
| Total cash and cash equivalents | | 659,873 | 203,264 |
| The above figures are reconciled to cash at the end of the financial period as shown in the Statement of Cash Flows. | | | |
| 5 Receivables | | | |
| Receivables | | 112,787 | 145,997 |
| Total receivables | | 112,787 | 145,997 |

| | Notes | Year Ended 2016 | Year Ended 2015 |
|--|-------|--------------------|--------------------|
| | | \$ | \$ |
| 6 Investments | | | |
| Available-for-sale financial assets at original value | | 3,337,000 | 3,725,000 |
| Changes in fair value of available for sale financial assets | | 61,350 | 298,319 |
| Total investments | | 3,398,350 | 4,023,319 |
| 7 Trade and other payables | | | |
| Trade payables | | 55,125 | 13,181 |
| Total trade and other payables | | 55,125 | 13,181 |
| 8 Equity | | | |
| Available-for-Sale financial assets reserve (i) | | 61,350 | 298,319 |
| Retained profits | | 4,053,461 | 4,061,093 |
| Total equity | | 4,114,811 | 4,359,412 |

(i) Available-for-sale financial assets reserve

Changes in the fair value of investments classified as available-for-sale financial assets are recognised in other comprehensive income, as described in note 1(h) and accumulated in a separate reserve within equity. Amounts are reclassified to profit or loss when the associated assets are sold or impaired.

9 Related party disclosures

Directors and other key management personnel

Apart from the amounts and issues disclosed in this note, there were no other transactions or balances with related parties during or at the end of the financial period.

Key management personnel compensation

| | | |
|---|--------|--------|
| Total key management personnel remuneration | 69,794 | 71,385 |
|---|--------|--------|

Controlling entities

From incorporation of the Company in August 2011 the sole members of the company are the directors of the company.

10 Lease commitments

The company's future minimum operating lease payments are as follows:

| | Minimum lease payments due | | | |
|--------------|----------------------------|--------------|---------------|-------|
| | Within 1 year | 1 to 5 years | After 5 years | Total |
| | \$ | \$ | \$ | \$ |
| 30 June 2016 | - | - | - | - |
| 30 June 2015 | - | - | - | - |

11 Members' guarantee

The Company was incorporated on 17 August 2011 as a Company limited by guarantee and not having a share capital. If the Company is wound up, the Constitution states that current Members (of which there are eight), and any persons whom were Members within the last 12 months immediately prior, are required to contribute an amount determined by the Company, but not exceeding \$100, to meet the outstanding obligations of the Company, if required.

12 Events occurring after the reporting date

There have been no events subsequent to balance date of a material nature.

13 Contingent liabilities

There are no contingent liabilities as at year end.

Directors' Declaration

In the directors' opinion:

- (a) the Financial Statements, comprising the Statement of Profit or Loss and Other Comprehensive Income, Statement of Financial Position, Statement of Cash Flows and Statement of Changes in Equity, and accompanying notes, as set out on pages 13 to 16 are in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, and:
 - (i) comply with Australian Accounting Standards – Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Regulations 2013*; and
 - (ii) give a true and fair view of the Company's financial position as at 30 June 2016 and of its performance for the financial period ended on that date; and
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



Dr Graeme Blackman
Chairman

Melbourne
15 August 2016



Grant Thornton

The Rialto, Level 30
525 Collins St
Melbourne Victoria 3000

Correspondence to:
GPO Box 4736
Melbourne Victoria 3001

T +61 3 8320 2222
F +61 3 8320 2200
E info.vic@au.gt.com
W www.grantthornton.com.au

Independent Auditor's Report To the Members of National Stem Cell Foundation of Australia

We have audited the accompanying financial report of National Stem Cell Foundation of Australia (the "Company"), which comprises the statement of financial position as at 30 June 2016, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information and the directors' declaration of the company.

Directors' responsibility for the financial report

The Directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the Australian Charities and Not-for-profits Commission Act 2012. The Directors' responsibility also includes such internal control as the Directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require us to comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error.

Grant Thornton Audit Pty Ltd ACN 130 913 594
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation. Liability is limited in those States where a current scheme applies.

In making those risk assessments, the auditor considers internal control relevant to the Company's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence

In conducting our audit, we have complied with the independence requirements of the Australian Charities and Not-for-profits Commission Act 2012.

Auditor's opinion

In our opinion:

- a the financial report of National Stem Cell Foundation of Australia is in accordance with the Australian Charities and Not-for-profits Commission Act 2012, including giving a true and fair view of the Company's financial position as at 30 June 2016 and of its performance for the year ended on that date; and
- b complying with Australian Accounting Standards – Reduced Disclosure Requirements and the Australian Charities and Not-for-profits Commission Regulation 2013.



GRANT THORNTON AUDIT PTY LTD
Chartered Accountants



Eric Passaris
Partner - Audit & Assurance

Melbourne, 15 August 2016